# Breast Cancer Research Program (Program 7)

> **NIH NIH P30** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $39,437

## Abstract

ABSTRACT – Breast Cancer Program 
The Breast Cancer Program (BC) was an outgrowth of the basic, translational, population and clinical research 
of the LCCC Breast Cancer SPORE, which has been continuously funded since 1992. LCCC investment in 
faculty and infrastructure supports one of the country's premier clinical and research breast programs, 
performing important interdisciplinary research of the past decade with members rising to leadership positions. 
This knitting together of clinical, basic, and epidemiologic research is the hallmark of the Breast Program, and 
is reflected in the investment in faculty and resources fostered by including over $10M in genomics/sequencing 
resources used for institutional as well as large multicenter trials and $7M in CBCS-III, which includes 
comprehensive biologic, traditional and molecular epidemiology, as well as treatment data and outcomes. This 
represents the largest and most heavily annotated population-based study ever performed addressing racial 
disparities in breast cancer, behavior and outcome. Other investments include the rapidly expanding Geriatric 
Oncology program, which has accrued over 2000 patients to molecular and functional geriatric studies. 
BC members capitalize on their discovery and understanding of intrinsic breast cancer subtypes to further 
characterize the distinguishing biological properties of breast cancer heterogeneity. Strategic goals include: 1) 
population-based studies identifying novel associations with breast cancer risk and hospital-based studies of 
alterations in normal breast and the breast tumor microenvironment, 2) bench-to-bedside approaches to 
therapeutics leveraging murine models and human window trials, 3) translational discovery and applied 
strategies including novel imaging and 4) correlative tissue biomarker studies nested within clinical trials. 
This mature Program and SPORE infrastructure includes clinicians, imaging innovators, statisticians, 
bioinformaticians, epidemiologists, and laboratory scientists utilizing the population and a range of models, 
from genetically engineered mice to the patient on into translational and clinical research protocols. We rely on 
novel approaches and applications in genomics, proteomics, imaging, informatics and clinical responses to 
analyze subtype specific biology, detection, metastatic potential and therapeutic efficacy. We perform clinical 
trials using novel therapeutic regimens, trial designs and biomarkers and we participate and analyze 
genomically some of the world's largest breast cancer trials. BC has substantial inter-programmatic 
interactions due to the LCCC's long term interest in North Carolina's minority disparities, following the 
program's seminal discoveries of the high incidence of TNBC in younger African Americans and surprising 
finding that the largest survival disparity is in women with hormone receptor-positive breast cancer. 
BC consists of 21 members from 3 different schools and cli...

## Key facts

- **NIH application ID:** 9834877
- **Project number:** 5P30CA016086-44
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** LISA A CAREY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $39,437
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9834877

## Citation

> US National Institutes of Health, RePORTER application 9834877, Breast Cancer Research Program (Program 7) (5P30CA016086-44). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9834877. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*